-Shoji Kudoh Researcher Activity Profile

Research Author Detailed Information 

Shoji Kudoh Publication Rate By Year

Shoji Kudoh has published 1 paper(s) in 2004, 1 paper(s) in 2005, 11 paper(s) in 2007, 8 paper(s) in 2008, for a total of 21 research publications in total.

Shoji S Kudoh Author Information

LAST NAME: kudoh

FIRST NAME: shoji

INITIALS: S

AFFILIATION:

Papers

Shoji Kudoh's Publication Record

1. Direct determination of MUC5B promoter haplotypes based on the method of single-strand conformation polymorphism and their statistical estimation. Year Published: 2004
Department of Respiratory Diseases, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
2. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Year Published: 2005
Department of Respiratory Diseases, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
3. Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Year Published: 2007
Respiratory Disease Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inba-mura, Chiba, Japan. y-ono@nms.ac.jp
4. Personalized medicine and proteomics: lessons from non-small cell lung cancer. Year Published: 2007
Respiratory Biological Sciences, AstraZeneca R&D Lund, SE-221 87 Lund, Sweden.
5. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Year Published: 2007
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.
6. Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Year Published: 2007
Respiratory Disease Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inba-mura, Chiba, Japan. y-ono@nms.ac.jp
7. Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib. Year Published: 2007
Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo 113-8602, Japan.
8. Microbial substitution of Mycobacterium avium-intracellulare to Mycobacterium abscessus during clinical course. Year Published: 2007
Department of Internal Medicine Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. s2069@nms.ac.jp
9. Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib. Year Published: 2007
Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo, Japan.
10. Development of a loop-mediated isothermal amplification method for diagnosing Pneumocystis pneumonia. Year Published: 2007
1Teikyo University Institute of Medical Mycology, 539 Otsuka, Hachioji, Tokyo 192-0395, Japan.
11. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Year Published: 2007
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.
12. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Year Published: 2008
Department of Respiratory Medicine, Tokyo Metropolitan Hiroo General Hospital, Tokyo.
13. Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib. Year Published: 2007
Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo, Japan.
14. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Year Published: 2008
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, Tokyo 113-8602, Japan.
15. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Year Published: 2008
Department of Respiratory Medicine, Tokyo Metropolitan Hiroo General Hospital, Tokyo.
16. Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Year Published: 2007
Respiratory Disease Center, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inba-mura, Chiba, Japan. y-ono@nms.ac.jp
17. Serum biomarker of lung carcinogenesis induced by cigarette smoking. Year Published: 2008
Department of Internal Medicine (Divisions of Pulmonary Medicine, Infectious Diseases, and Oncology), Nippon Medical School.
18. Serum biomarker of lung carcinogenesis induced by cigarette smoking. Year Published: 2008
Department of Internal Medicine (Divisions of Pulmonary Medicine, Infectious Diseases, and Oncology), Nippon Medical School.
19. E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. Year Published: 2008
Department of Pulmonary Medicine/Infection and Oncology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan.
20. Tiotropium Ameliorates Symptoms in Patients with Chronic Airway Mucus Hypersecretion which is Resistant to Macrolide Therapy. Year Published: 2008
Department of Internal Medicine (Divisions of Pulmonary Medicine, Infectious Diseases, and Oncology), Nippon Medical School.
21. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to macrolide therapy. Year Published: 2008
Department of Internal Medicine, Division of Pulmonary Medicine, Nippon Medical School, Tokyo, Japan. yo-saito@nms.ac.jp